News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Evotec AG Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance With Roche
March 10, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HAMBURG, Germany, March 10, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Clinical research
Phase I
Europe
Roche
MORE ON THIS TOPIC
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
January 2, 2026
·
2 min read
·
Nick Paul Taylor
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
December 23, 2025
·
2 min read
·
Nick Paul Taylor
Legal
Investment Banker Accused of Leaking Pharma M&A Secrets in $41M Insider Trading Scheme
December 23, 2025
·
2 min read
·
Nick Paul Taylor
Clinical research
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A
December 23, 2025
·
1 min read
·
Annalee Armstrong
